NCT04176991已完成1 期
A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Number of Participants with Treatment-Emergent Adverse Events
研究概览
简要总结
To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia
详细描述
Single Ascending Dose (SAD), Double-Blind, Placebo Controlled Study.
To evaluate the safety and tolerability of single ascending doses of CTI-1601 in subjects with Friedreich's ataxia.
Secondary Objectives:
- To evaluate the pharmacokinetics (PK) of CTI-1601 following increasing single doses of subcutaneously (SC) administered CTI-1601.
- To evaluate the pharmacodynamics (PD) of CTI-1601 following increasing single doses of SC administered CTI-1601.
CTI-1601 or Placebo - Dose/Mode of Administration: Single Dose/Subcutaneous
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has genetically confirmed Friedreich's ataxia diagnosis, homozygous GAA repeat expansions, with repeat sizing (if available) included on diagnostic report.
- •Subject is male or female, 18 years of age or older at screening.
- •Subject must have a mFARS_neuro score ≥ 20 and be able to traverse a distance of 25 feet with or without some assistive device (cane, walker, crutches, self-propelled wheelchair) and (a) be able to sit upright with thighs together and arms crossed without requiring support on more than two sides; (b) be able to transfer from bed to chair independently or with minimal assistance if, in the opinion of the investigator, the degree of physical disability does not result in undue risk to the subject while participating in the study; and (c) perform basic daily care, such as feeding themselves and personal hygiene, with minimal assistance.
- •Subjects must weigh > 40 kilograms (kg).
排除标准
- •Subjects who are confirmed as compound heterozygous (GAA repeat expansion on only one allele) for Friedreich's ataxia.
- •Subject requires use of amiodarone.
- •Subject used erythropoietin, etravirine, or gamma interferon within 3 months prior to screening.
- •Subject use of investigational drug (other than CTI-1601) or device within 90 days prior to screening.
- •Subject use of daily biotin supplementation that exceeds 30 mcg/day, either as part of a multivitamin or as a standalone supplement, within 7 days prior to study drug administration and/or throughout the entire study.
- •Subject has clinically significant arrhythmia on electrocardiogram (ECG), or evidence of predisposition to significant ventricular arrhythmia on ECG, or evidence of active and unstable coronary artery disease.
- •Male subject who has an ECG QTcF > 450 milliseconds or female subject who has an ECG QTcF > 470 milliseconds.
- •Subject has a screening echocardiogram ejection fraction <45 percent.
- •Subject has a history of aspiration, aspiration pneumonia, or recurrent episodes of pneumonia (greater than or equal to 2 episodes of pneumonia) within the last 12 months.
- •Subjects with known or suspected chronic use of cannabinoid products.
结局指标
主要结局
Number of Participants with Treatment-Emergent Adverse Events
时间窗: Through study completion, an average of 70 days
Overall summary of the Participants with Treatment Emergent Adverse Events
Number of Treatment Emergent Adverse Events by System Organ Classification and Preferred Term
时间窗: Through study completion, an average of 70 days
Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 22.0)
次要结局
- Pharmacokinetics - Area under the concentration-time curve after a single dose(Up to 48 hours)
- Pharmacokinetics - Time to reach maximum plasma concentration after a single dose(Up to 48 hours)
- Pharmacokinetics - Apparent total plasma clearance(48 hours)
- Pharmacokinetics - Terminal half-life estimation(48 hours)
- Pharmacokinetics - Apparent volume of distribution(48 hours)
- Changes in Gene Expression Profiling(At baseline and up to 10 days)
- Pharmacokinetics - Maximum observed plasma concentration after a single dose(Up to 48 hours)
- Pharmacokinetics - Area under the concentration-time curve from time 0 to infinity(48 hours)
- Pharmacokinetics - Area under the concentration-time curve from time 0 to the last measurable time point(48 hours)
- Changes from Baseline in Frataxin Levels in Buccal Cells(At baseline and up to 10 days)
- Changes from Baseline in Frataxin Levels in Whole Blood(At baseline and up to 10 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of OA-235i in Subjects With Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisNonalcoholic Fatty LiverNCT05680233Oasis Pharmaceuticals, LLC24
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy ParticipantsHepatitis Delta VirusHepatitis DNCT06740474Assembly Biosciences40
招募中
1 期
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusDiabete Type 2NCT05268237Biolingus15
终止
1 期
A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The SkinCachexiaNCT01262690Pfizer44
Unknown
1 期
A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid TumorsAdvanced Tumor of Digestive Tract or Urinary SystemNCT05499715Chinese Academy of Medical Sciences48